Overview

• Combined rapamycin and trametinib treatment extended mouse median and maximum lifespans by around 30%, exceeding results from either drug alone.
• Treated mice exhibited reduced chronic inflammation in multiple organs and delayed tumour development, signalling improved health in old age.
• Analysis of gene activity showed the dual therapy induces distinct transcriptional changes not seen with individual drugs.
• Rapamycin and trametinib are already approved for cancer treatment, positioning them as strong candidates for geroprotector studies in humans.
• Next steps involve optimising trametinib dose and delivery route to maximise benefits and minimise adverse effects before human testing.